Carbamazepine

Generic Name: Carbamazepine

Brand Names: Carbatrol, Carnexiv, Epitol, Equetro, Tegretol

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₂N_₂O

CAS Number: 298-46-4

Unique Ingredient Identifier: 33CM23913M

Background: Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant use...

Indication: Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive e...

Associated Conditions: Acute Mania, Alcohol Withdrawal Syndrome, Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Mixed manic depressive episode, Pain, Partial Seizures With Secondary Generalization, Restless Legs Syndrome (RLS)

Associated Therapies: -

Clinical Trials

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Drug: EDP-514
Drug: Quinidine
Drug: Carbamazepin
Drug: Itraconazole

First Posted Date: 2021-03-05

Last Posted Date: 2021-08-16

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 72

Registration Number: NCT04783753

Locations: 🇺🇸
Pharmaceutical Research Association, Lenexa, Kansas, United States

Changing Agendas on Sleep, Treatment and Learning in Epilepsy

Phase 4

Terminated

Conditions: Rolandic Epilepsy

Interventions: Drug: Levetiracetam
Drug: Carbamazepine
Behavioral: Parent based sleep (PBS) intervention

First Posted Date: 2020-11-02

Last Posted Date: 2020-11-02

Lead Sponsor: King's College London

Target Recruit Count: 5

Registration Number: NCT04610879

Locations: 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
Whiston Hospital, Whiston, United Kingdom
🇬🇧
Tameside Hospital, Manchester, United Kingdom

Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients

Completed

Conditions: Pain, Neuropathic
Trigeminal Neuralgia
Multiple Sclerosis

First Posted Date: 2020-05-01

Last Posted Date: 2020-05-01

Lead Sponsor: Stine Maarbjerg, MD PhD

Target Recruit Count: 60

Registration Number: NCT04371575

A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Erdafitinib
Drug: Carbamazepine

First Posted Date: 2020-04-01

Last Posted Date: 2023-06-29

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 15

Registration Number: NCT04330248

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

Population Pharmacokinetics of Antiepileptic in Pediatrics

First Posted Date: 2017-06-22

Last Posted Date: 2024-10-30

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 1000

Registration Number: NCT03196466

Locations: 🇫🇷
AP-HP Cochin, Paris, France

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Carbamazepine
Drug: Eslicarbazepine

First Posted Date: 2016-09-23

Last Posted Date: 2019-06-04

Lead Sponsor: Stanford University

Target Recruit Count: 46

Registration Number: NCT02912364

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Cost- Effectiveness and Quality of Life Assessment in Mood Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium
Drug: Valproic Acid
Drug: Carbamazepine

First Posted Date: 2016-08-17

Last Posted Date: 2020-11-20

Lead Sponsor: Federal University of Rio Grande do Sul

Target Recruit Count: 107

Registration Number: NCT02870283

Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures

Phase 4

Completed

Conditions: Seizures, Focal

Interventions: Drug: Oxcarbazepine
Drug: Carbamazepine

First Posted Date: 2016-03-11

Last Posted Date: 2017-09-19

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 90

Registration Number: NCT02705768

Locations: 🇮🇳
AIIMS, Bhubaneswar, Bhubaneswar, Odisha, India

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

Phase 4

Terminated

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Carbamazepine

First Posted Date: 2015-12-07

Last Posted Date: 2023-03-03

Lead Sponsor: Validus Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT02623504

Locations: 🇺🇸
APG Research, LLC, Orlando, Florida, United States
🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸
Red Oak Psychiatry Associates, PA, Houston, Texas, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy